TG Therapeutics raises 2026 BRIUMVI revenue forecast to $885-900M after strong Q1 sales.

TG Therapeutics reported Q1 2026 global revenue of about $205 million, driven by $195 million in U.S. sales of BRIUMVI, a treatment for multiple sclerosis. The company raised its full-year 2026 revenue guidance to approximately $925 million, with BRIUMVI U.S. net product revenue now expected between $885 million and $900 million, up from prior estimates. This growth is fueled by strong demand, record new patient starts, and ongoing commercial efforts. TG Therapeutics also highlighted upcoming clinical trial milestones and expanded its share repurchase program, signaling confidence in BRIUMVI's long-term potential as a leading MS therapy.